Trimetazidine modified release in treatment of patients with the serious course of chronic ischemic heart disease: from the theory to real clinical practice

Trimetazidine modified release in treatment of patients with the serious course of chronic ischemic heart disease: from the theory to real clinical practice

The paper considers modern conceptions about the role of citoprotective therapy in persons with ischemic heart disease. Special attention is given to the justification of Trimetazidine modified release (TMZ MV) application in patients with severe multi-vessel coronary lesions in conjunction with lef...

Full description

Bibliographic Details
Main Authors:	A. V Barsukov, D. V Glukhovskoy
Format:	Article
Language:	English
Published:	Concilium Medicum 2014-03-01
Series:	КардиоСоматика
Subjects:	ischemic heart disease multivessel lesion systolic dysfunction drug treatment trimetazidine modified release
Online Access:	https://cardiosomatics.orscience.ru/2221-7185/article/view/45087

Similar Items

The effectiveness of cytocardioprotection of patients with the moderately expressed post infarct dysfunction of left heart ventricle: the results of the randomization research of trimetazidine and athenolole
by: V. V. Kalyuzhin, et al.
Published: (2002-03-01)

THE PROBLEM OF INTERCHANGEABILITY OF DRUG PRODUCTS. TRIMETAZIDINE IS AN EFFECTIVE TREATMENT OF PATIENTS WITH ISCHEMIC HEART DISEASE
by: L. E. Chekuldaeva, et al.
Published: (2015-12-01)

AN EXPERIENCE OF TRIMETAZIDINE USAGE IN COMORBIDITY
by: I. V. Kochetkova, et al.
Published: (2018-04-01)

Effects of sustained-release trimetazidine on chronically dysfunctional myocardium of ischemic dilated cardiomyopathy – Six months follow-up result
by: A. Momen, et al.
Published: (2016-11-01)

Evaluation of the efficiency of combined pharmacotherapy with the use of trimetazidine with prolonged release in patients with stable angina in outpatient practice
by: Yu V Luneva, et al.
Published: (2019-08-01)

TRIMETAZIDINE INFLUENCE ON FILTRATION AND TUBULOINTERSTITIAL FUNCTION OF KIDNEYS IN ISCHEMIC HEART DISEASE PATIENTS WITH CHRONIC HEART FAILURE AND RENAL DYSFUNCTION
by: N. A. Koziolova, et al.
Published: (2018-03-01)

Trimetazidine in Heart Failure
by: Hongyang Shu, et al.
Published: (2021-01-01)

Clinicohemodynamic efficacy of a selective beta-blocker bisoprolol and cytoprotector trimetazidine in the treatment of chronic cardiac failure in patients with ischemic heart disease
by: Т A Fedorova, et al.
Published: (2004-03-01)

Anti-anginal and anti-ischemic effectiveness of trimetazidine MB in patients with unstable angina
by: M. G. Glezer, et al.
Published: (2009-02-01)

CLINICAL EFFECTIVENESS OF THE MODIFIED RELEASE TRIMETAZIDINE IN MICROVASCULAR ANGINA
by: P. Yu. Galin, et al.
Published: (2016-12-01)

Effects of trimetazidine and perindopril on myocardialfunction and metabolism in postmyocardial infarction patients with cardiac failure
by: A V Shabrov, et al.
Published: (2003-09-01)

Features of anti-ischemic efficacy of trimetazidine MR, assigned in combination with metoprolol in patients with angina
by: P. Yu Bardybakhin, et al.
Published: (2013-03-01)

Attenuation of endoplasmic reticulum stress and mitochondrial injury in kidney with ischemic postconditioning application and trimetazidine treatment
by: Mahfoudh-Boussaid Asma, et al.
Published: (2012-08-01)

Analysis about the effect of trimetazidine combined with atorvastation calcium on myocardin i level, cardiac and renal function in patients with ischemic cardiomyopathy
by: Li-Bing Chen, et al.
Published: (2017-06-01)

TRIMETAZIDINE THERAPY INFLUENCE ON HEART RATE VARIABILITY IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE
by: M. V. Novikova, et al.
Published: (2014-10-01)

Cliniko-experimental research of trimetazidine efficiency at the myocardium ischemia
by: O. V Romashchenko
Published: (2013-06-01)

Trimetazidine-Induced Parkinsonism: A Systematic Review
by: Anna Marielle B. Dy, et al.
Published: (2020-02-01)

Effectiveness of the original trimetazidine MR in patients with stable coronary heart disease and angina attacks resistant to trimetazidine generics (ETALON study)
by: A. V. Fendrikova, et al.
Published: (2011-08-01)

Trimetazidine effects on mitochondria energetic activity
by: S. V. Eliseeva, et al.
Published: (2008-12-01)

CORRECTION OF MORPHOFUNCTIONAL DISORDERS IN EXPERIMENTAL PREECLAMPSY BY COMBINED USE OF TRIMETAZIDINE AND PURIFIED MICRONIZED FLAVONOID FRACTION AS WELL AS THEIR COMBINATIONS WITH METHYLAMPSY
by: O. E. Antsiferova, et al.
Published: (2021-03-01)

THE USAGE OF TRIMETAZIDINE IN COMPLEX TREATMENT OF HEART FAILURE
by: N. R. Paleev, et al.
Published: (2001-04-01)

The cardioprotective role of trimetazidine on cisplatin-induced cardiotoxicity
by: Murathan Küçük, et al.
Published: (2020-01-01)

CYTOPROTECTION WITH TRIMETAZIDINE MB: RECENT DATA
by: I. G. Gordeev, et al.
Published: (2015-05-01)

ANTIISCHEMIC METABOLIC MODULATOR TRIMETAZIDINE IN TREATMENT OF CORONARY HEART DISEASE
by: V. P. Lupanov
Published: (2017-02-01)

Efficacy of Trimetazidine and Sulodexide in Patients with Microvascular Angina
by: S. A. Boldueva, et al.
Published: (2020-07-01)

MYOCARDIAL CYTOPROTECTOR TRIMETAZIDINE MB-PREPARAT, INCREASES THE EFFECTIVENESS OF TREATMENT OF CHRONIC HEART FAILURE AND CORONARY HEART DISEASE
by: D. I. Trukhan, et al.
Published: (2017-12-01)

INFLUENCE OF TRIMETAZIDINE METABOLIC THERAPY ON CONNECTIVE TISSUE METABOLISM IN EXPERIMENTAL DIFFUSE ISCHEMIC NECROTIC CARDIOSCLEROSIS IN RATS WITH DIFFERENT RATES OF HYPOXIA RESISTANCE
by: H. S. Saturska, et al.
Published: (2016-05-01)

TRimetazidine as an Agent to affeCt clopidogrEl Response: The TRACER Study
by: Naveen Seecheran, et al.
Published: (2019-07-01)

RATIONALE FOR APPLICATION, AND BENEFITS OF TRIMETAZIDINE IN HEART FAILURE BY ITS INFLUENCE OF MYOCARDIUM METABOLISM
by: Yu. M. Lopatin, et al.
Published: (2016-08-01)

Trimetazidine Effects on Neutrophils Count in Patients Post PPCI
by: Taka Mehi, et al.
Published: (2015-12-01)

Trimetazidine Attenuates Cardiac Dysfunction in Endotoxemia and Sepsis by Promoting Neutrophil Migration
by: Jing Chen, et al.
Published: (2018-09-01)

Protective Role of Trimetazidine Against Neomycin-induced Hair Cell Damage in Zebrafish
by: Jiwon Chang, et al.
Published: (2013-12-01)

Clinical effectiveness of long-term trimetazidine MB therapy in patients with cardio-respiratory disease (the results of an open, prospective multi-centre study)
by: N. M. Kolomoets, et al.
Published: (2009-12-01)

Trimetazidine MB treatment in patients with chronic heart failure
by: T. E. Morozova, et al.
Published: (2010-06-01)

METABOLIC MYOCARDIAL CYTOPROTECTORS IN THERAPY OF STABLE ISCHEMIC HEART DISEASE: EVIDENCE OF EFFECTIVENESS AND USE RECOMMENDATIONS
by: N. B. Perepech
Published: (2017-11-01)

CURRENT APPROACHES TO EVALUATION OF THE MULTIVESSEL CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE
by: D. N. Perutsky, et al.
Published: (2016-01-01)

Trimetazidine MR effects on heart remodeling in stable coronary heart disease patients
by: E. M. Khurs, et al.
Published: (2007-02-01)

Trimetazidine in chronic heart failure patients aged above 75 years
by: I. V. Ignatenko, et al.
Published: (1970-01-01)

MANAGEMENT OF ANGINA ATTACKS IN HEART FAILURE DUE TO NONCORONARY HEART DISEASE: TRIMETAZIDINE USAGE
by: M. Yu. Sitnikova, et al.
Published: (2015-11-01)

Feasibility of optimizing trimetazidine dihydrochloride release from controlled porosity
by: Basant A. Habib, et al.
Published: (2014-05-01)